Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing

SET, ESS, JAM, GMF, LAA and JV are employees of Foundation Medicine, Inc. SLM and CRB are employees of Genentech, Inc. SET, ESS, SLM, JAM, GMF, LAA, MZO, JV and CRB have ownership interest in Roche. LHS holds consultancy and honoraria with Roche, Genentech, Abbie, Amgen, Celgene, Janssen, Lundbeck, Seattle Genetics, Merck, TG Therapeutics, Mophosys and Karyopharm. This study was supported by Foundation Medicine, Inc., Genentech, Inc., and F. Hoffmann-La Roche Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

留言 (0)

沒有登入
gif